Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK to Invest £200 Million in UK Manufacturing

Published: Thursday, December 12, 2013
Last Updated: Thursday, December 12, 2013
Bookmark and Share
The series of investments will support the delivery of the company’s pipeline of new medicines and create a centre for pharmaceutical manufacturing innovation in the UK.

Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment. In addition GSK will establish a new facility dedicated to harnessing innovative technologies with the potential to transform both the way medicines are made and the company’s supply chain.

Roger Connor, GSK’s President of Global Manufacturing and Supply, said: “The establishment of the Patent Box has transformed how we see the UK as a place to invest. As a result, last year we announced we were building our first new factory in the UK for 40 years. The investments announced today are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines. These new technologies could significantly reduce costs, improve quality and enable the manufacture of medicines in weeks rather than years and I am delighted that we have been able to bring these investments to the UK.”

Jeremy Hunt, Health Secretary, said: "On the day when we are bringing together the health leaders of the developed world, researchers and pharmaceutical countries to launch the global fight against dementia, it is great to see GSK investing more money and resources into UK life sciences. GSK's decision to invest in the UK shows we are creating the right conditions for global investment, leading to job creation and growth, as well as maintaining the UK's place as a world leader in innovation."

The investments announced today comprise:

  • New manufacturing facilities in Ware for the RelvarTM ElliptaTM inhaler – the latest generation of GSK’s inhaler devices for respiratory disease. The Ellipta device was developed at Ware and will now be produced at the site before being exported worldwide.

  • In Worthing, a new bulk sterile building and filling line will be built for the company’s leading antibiotic medicine AugmentinTM, which is exported to 150 countries.

  • A new centre for manufacturing innovation will be built, dedicated to transforming emerging science and technologies into practical manufacturing applications. These technologies range from mimicking nature using enzymes and biologically inspired catalysts, to using nano-technologies to create intelligent drug product formulations which minimise side-effects and enhance efficacy. Although subject to further decisions, GSK’s preferred site for the location of the new centre is Ware, Hertfordshire where the company already has manufacturing and R&D facilities in one location.

The establishment of the Patent Box has made the UK a globally competitive location for investment in high-tech manufacturing and research facilities. Today’s investment is on top of the £500 million GSK announced in March last year which included a commitment to build a new factory in Ulverston, Cumbria. That investment is creating up to 1,000 jobs and continues to progress on schedule. GSK also recently announced an investment of £25 million to expand its operations in Montrose to support the delivery of its new pipeline of medicines.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK, Francis Crick Institute Collaborate
This partnership sets out to explore new avenues of medical research and drug discovery across a broad range of diseases, with a view to achieving breakthroughs in the understanding of human disease.
Monday, July 20, 2015
GSK’s 2015 Discovery Fast Track Challenge
Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US.
Wednesday, March 25, 2015
Malaria Vaccine Could be Available from 2015
GSK candidate reduces disease over 18 Months of follow-up in late-stage study of more than 15,000 infants and young children.
Tuesday, October 08, 2013
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!